Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 5 Urothelial Cancer 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Urinary Bladder Diseases 1 Ureteral Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms by Site 1 Neoplasms 1 Male Urogenital Diseases 1 Female Urogenital Diseases 1 Carcinoma, Transitional Cell 1 Advanced Bladder Cancer 1

Interventions

pembrolizumab 1 enfortumab vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Bladder Cancer × enfortumab vedotin × Clear all

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡